Kailera CTO granted options on 220K shares

Kailera Therapeutics’ Chief Technology Officer received a sizable time-vested stock option grant as part of equity compensation.

Available on EDGAR 09/09/2026 - 07:30 PM EDT Accepted by SEC EDGAR 09/09/2026 - 07:29 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Kailera Therapeutics, Inc. (KLRA) reported that its Chief Technology Officer, Nicholson Nur, received a grant of stock options to acquire 220,000 shares of common stock on September 7, 2026 at an exercise price of $16.23 per share, expiring September 7, 2036.

The options vest as to 25% of the underlying shares on August 31, 2027 and thereafter in 36 substantially equal monthly installments, subject to Nur’s continued service through each vesting date. No Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Grant/Award: 220,000 shares

Grant/Award 1 txn

Insider Nicholson Nur

Role Chief Technology Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	220,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 220,000 contracts (Direct)

Holdings Before and After: Stock Option (right to buy), 0 to 220,000 contracts (Direct)

Footnotes (1)

1. F1. The options vest and become exercisable as to 25% of the underlying shares on August 31, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date.

Key Figures

Stock options granted: 220,000 options Exercise price: $16.23 per share Expiration date: September 7, 2036 +3 more

6 metrics

Stock options granted 220,000 options Grant to Chief Technology Officer on September 7, 2026

Exercise price $16.23 per share Exercise price of options granted on September 7, 2026

Expiration date September 7, 2036 Expiration of the granted stock options

Initial vesting tranche 25% of underlying shares Vests on August 31, 2027, subject to continued service

Remaining vesting period 36 monthly installments Vests in substantially equal monthly installments after August 31, 2027

Options held after transaction 220,000 options Total related options reported as directly held following the grant

Key Terms

Stock Option, underlying shares, vest

3 terms

Stock Option financial

"Stock Option (right to buy)"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

underlying shares financial

"25% of the underlying shares on August 31, 2027"

vest financial

"The options vest and become exercisable as to 25% of the underlying shares"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did KLRA report for Nicholson Nur?

Kailera Therapeutics reported that Chief Technology Officer Nicholson Nur received a stock option grant for 220,000 underlying shares of common stock on September 7, 2026, with an exercise price of $16.23 per share and expiration on September 7, 2036.

How many KLRA shares are covered by Nicholson Nur’s new stock options?

The grant covers 220,000 underlying shares of Kailera Therapeutics common stock. Following this award, the Form 4 reports 220,000 options held by Nicholson Nur related to this grant.

What is the exercise price and term of Nicholson Nur’s KLRA options?

The stock options have an exercise price of $16.23 per share and an expiration date of September 7, 2036, giving Nicholson Nur the right to buy Kailera Therapeutics common shares at that price until that date, subject to vesting.

What is the vesting schedule for Nicholson Nur’s KLRA stock options?

The options vest and become exercisable as to 25% of the underlying shares on August 31, 2027 and thereafter in 36 substantially equal monthly installments, subject to Nicholson Nur’s continued service through each vesting date.

Were any KLRA shares sold by Nicholson Nur in this Form 4?

No. The Form 4 reports only a grant of stock options to Nicholson Nur covering 220,000 underlying shares; it does not report any sales or dispositions of Kailera Therapeutics common stock.

Was Nicholson Nur’s KLRA option grant made under a Rule 10b5-1 plan?

No. The filing indicates no Rule 10b5-1 trading plan applies to this reported stock option grant to Nicholson Nur.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nicholson Nur

(Last) (First) (Middle)

C/O KAILERA THERAPEUTICS, INC.

180 THIRD AVENUE, 4TH FLOOR

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kailera Therapeutics, Inc. [ KLRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$16.23	09/07/2026		A		220,000		(1)	09/07/2036	Common Stock	220,000	$0	220,000	D

Explanation of Responses:

1. The options vest and become exercisable as to 25% of the underlying shares on August 31, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date.

	/s/ John Mei, Attorney-in-fact	09/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)